Warfarin: a case history in pharmacogenetics

A M Hall, M R Wilkins

Both hereditary and environmental factors contribute to inter-individual variability in drug response. The considerable interest in the role of genes has to be balanced with the contribution of external influences. Warfarin provides a useful case study of the need to integrate both genetic and non-genetic information when selecting the right dose for a patient. This article discusses the latest data on genotype and warfarin sensitivity and the efforts to incorporate this information into normograms. Exploring the genetics of warfarin response will lead not only to safer prescribing but elucidate the mechanism of action of warfarin and enable the development of new anticoagulant drugs.

Pharmacogenetics—the use of genetic information to inform the prescribing of drugs—has caught the imagination of clinicians, scientists, and patients alike. It promises greater precision in prescribing, where treatment is tailored to the individual, improving the chances of therapeutic response and reducing the risk of harm. While this is highly desirable, it is important not to lose sight of the fact that environment and behaviour also influence the effect of a drug. At best, genotype will be only one of a number of factors that need to be considered when prescribing for a patient. Warfarin provides a good illustration of the complex interplay between genes and environment in determining patient response and the practical issues in delivering on personalised medicines.

Warfarin is currently the most widely used oral anticoagulant in the world. Individual response to the drug is highly variable. In a given population, prescribed doses can vary from 1–40 mg or more daily. Importantly, the therapeutic index in any one patient is very narrow. Patients are monitored closely using the international normalised ratio (INR) for prothrombin time but this adds expense and the incidence of bleeding complications, estimated at 7.6 to 16.5 per 100 patient years, remains high. The period of highest risk of bleeding complications is around the start of warfarin treatment. In an ideal setting, the physician would like to predict the dose required for each patient without the need for trial and error.

WARFARIN SENSITIVITY

As any medical student will recall, many clinical and behavioural factors influence the response to warfarin and need to be considered when prescribing the drug. These include diet, alcohol intake, body mass, concomitant drug treatment, co-existing disease, and patient compliance. Genes are also important. The first gene affecting warfarin sensitivity to be identified was CYP2C9. This gene encodes the enzyme (CYP2C9) responsible for metabolising the pharmacologically more potent S-enantiomer of warfarin to inactive metabolites. A least six single nucleotide polymorphisms (SNPs) of CYP2C9 have been found which may influence enzyme activity. Studies show that the 2C9*2 and 2C9*3 variants have 12% and 5% of the enzyme activity of the wild-type allele, 2C9*1, and that patients with these variant alleles require significantly lower doses of warfarin than patients with the wild-type gene, with evidence of a gene–dose effect (such that homozygotes are more sensitive than heterozygotes). These variants are associated with a significantly increased risk of bleeding during induction of anticoagulation with warfarin, but not during maintenance.

WARFARIN RESISTANCE

At the other end of the spectrum, inherited resistance to warfarin is well recognised in rats, mice, and humans. Warfarin acts by inhibiting the enzyme vitamin K epoxide reductase (VKOR). This enzyme recycles vitamin K epoxide to reduced vitamin K (fig 1). The latter is oxidised back to vitamin K epoxide in a coupled reaction that causes carboxylation and activation of the coagulation factors II, VII, IX, and X (the so called “vitamin K dependent clotting factors” which make up the intrinsic coagulation pathway). Until this year, little was known about VKOR as it had been only partially purified and its gene had not been identified. In an elegant series of experiments using family linkage studies and rodent genetics, two groups have identified a gene (termed vitamin K epoxide reductase complex subunit 1 or VCORC1) with a central role in determining VKOR activity. VKOR was thought to be a large multicomplex protein, but expressing the product of VKORC1 alone bestowed VKOR activity in insect cells that did not have it while targeted inhibition of VCorC1 expression with small interfering RNAs notably reduced VKOR activity. Thus, this molecule alone may be responsible for recycling vitamin K. Missense mutations in this gene appear to explain inherited warfarin resistance in humans and rats.

IMPLICATIONS FOR WARFARIN PRESCRIBING

How might this genetic information influence our use of warfarin? In general terms, the value of genotyping a patient for a given variant would be...

See end of article for authors’ affiliations

Correspondence to: Professor Martin R Wilkins, Experimental Medicine & Toxicology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; m.wilkins@imperial.ac.uk
Coagulation factors II/VII/IX/X

Active forms

Vitamin K hydroquinone

Vitamin K epoxide

Vitamin K reductase

Active forms

Vitamin K epoxide reductase

Oral vitamin K

Warfarin

Figure 1 Cylical reduction and oxidation of vitamin K is inhibited by warfarin. Dietary vitamin K is reduced to vitamin K hydroquinone by vitamin K reductase. Vitamin K hydroquinone is then oxidised to vitamin K epoxide in a coupled reaction which results in the activation of coagulation factors II, VII, IX, and X. Vitamin K epoxide is then reduced back to vitamin K by vitamin K epoxide reductase (VKOR). This enzyme is inhibited by warfarin, leading to a block in the cycle, which results in a depletion in activated clotting factors.

depends upon the frequency of the allele, the mode of effect (autosomal dominant/recessive), the size of the gene effect, and cost. Inactivating CYP2C9 alleles are not uncommon, being found in 35% of the white population. At least three studies have explored the contribution of genotype alone and together with demographic and clinical factors to determining the maintenance dose of warfarin. In univariate analyses, CYP2C9 genotype alone appears to account for between 10–20% of the variability in maintenance dose of warfarin. Taking genotype along with factors such as age, body surface area, sex, and concomitant drug use, explained between 29–39% of the variability in warfarin dose. Gage and colleagues have devised a normogram, using genotype and other factors available at the time of starting treatment with warfarin, to estimate warfarin requirements before commencing treatment and argue that its use would reduce the risk of bleeding around the time of initiating anticoagulation with the drug. They concede that it would not eliminate the need for INR monitoring and recognise that use of the normogram needs to be evaluated for cost effectiveness in a prospective study.

Conversely, heredity resistance to warfarin is rare. Whether there are common polymorphisms of VKORC1 with significant effects on warfarin sensitivity in the general population is now the subject of further study. For the present, routine genotyping for VKORC1 variants is not indicated. It would be of diagnostic value when a patient appears to require a particularly high dose of warfarin; the demonstration that the patient had genetically determined resistance would indicate the need for an anticoagulant with a different mode of action.

DEVELOPING BETTER DRUGS

But there is more than one gain from pharmacogenetic studies of this sort. Pharmacology can inform disease genetics and genetic strategies can lead to the development of better drugs. In this case, VKORC1 allelic variants are not only responsible for warfarin resistance but can also give rise to hereditary deficiency of vitamin K dependent clotting factors. Meanwhile, clarifying the molecular target for warfarin permits more detailed study of the structure and function of this enzyme and the possibility of new pharmacological inhibitors, ideally with different kinetics and less inter-individual variability.

Authors’ affiliations

A M Hall, M R Wilkins, Experimental Medicine & Toxicology, Imperial College, Hammersmith Hospital, London, UK

REFERENCES


Warfarin: a case history in pharmacogenetics

A M Hall and M R Wilkins

*Heart* 2005 91: 563-564
doi: 10.1136/hrt.2004.051771

Updated information and services can be found at:
http://heart.bmj.com/content/91/5/563

These include:

References
This article cites 19 articles, 2 of which you can access for free at:
http://heart.bmj.com/content/91/5/563#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/